MedTrace Logo

Riptylimab for the Treatment of Optic Neuritis and Myelitis Spectrum Diseases

NCT07685678 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-06

No results posted yet for this study

Summary

This clinical trial aims to evaluate the safety and efficacy of ripertamab in patients with neuromyelitis optica spectrum disorders (NMOSD). The key research objectives are as follows:

1. To assess the efficacy of ripertamab for the treatment of neuromyelitis optica spectrum disorders.
2. To assess the safety of ripertamab for the treatment of neuromyelitis optica spectrum disorders.

Study participants are required to:

Receive a single intravenous infusion of ripertamab. Attend follow-up examinations and laboratory tests at the study site at Week 1, Week 9, Week 17, Week 25, Week 33, Week 41, Week 49, Week 57, Week 65, Week 73, Week 81, Week 89, Week 97.

Maintain a daily symptom diary and record the number of rescue treatments.

Conditions

  • Neuromyelitis Optica Spectrum Disease (NMOSD)
  • Ripertamab

Interventions

DRUG

Riptylimab

Administer Ripeltumab Injection 500 mg intravenously on W1D1, W25D1, W49D1 and W73D1 of the treatment period

Sponsors & Collaborators

  • Zhongming Qiu

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2030-01-01
Completion
2030-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07685678 on ClinicalTrials.gov